Casdin Capital
Latest statistics and disclosures from Casdin Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are BLFS, RVMD, WGS, LAB, SRPT, and represent 55.00% of Casdin Capital's stock portfolio.
- Added to shares of these 10 stocks: ILMN (+$35M), CDXS (+$19M), LAB (+$14M), SNDX (+$6.3M), GH (+$5.7M), RLAY (+$5.7M), VERV, FDMT, GRAL, BEAM.
- Started 1 new stock position in Ginkgo Bioworks Holdings Inc Cl A.
- Reduced shares in these 10 stocks: RVMD (-$13M), PLRX (-$11M), DNLI (-$9.0M), VCYT (-$6.5M), KYTX, IPSC, GLUE, WGS, DNA, OMIC.
- Sold out of its positions in DNA, KYTX, PLRX, OMIC.
- Casdin Capital was a net buyer of stock by $51M.
- Casdin Capital has $1.5B in assets under management (AUM), dropping by 14.53%.
- Central Index Key (CIK): 0001534261
Tip: Access up to 7 years of quarterly data
Positions held by Casdin Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Casdin Capital
Casdin Capital holds 35 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Biolife Solutions Com New (BLFS) | 14.5 | $218M | 8.7M | 25.04 |
|
|
| Revolution Medicines (RVMD) | 12.4 | $187M | -6% | 4.1M | 45.35 |
|
| Genedx Holdings Corp Com Cl A (WGS) | 9.9 | $149M | 3.5M | 42.44 |
|
|
| D Fluidigm Corp Del (LAB) | 9.2 | $138M | +11% | 71M | 1.93 |
|
| Sarepta Therapeutics (SRPT) | 8.9 | $134M | 1.1M | 124.89 |
|
|
| Illumina (ILMN) | 6.5 | $98M | +56% | 750k | 130.41 |
|
| Avidity Biosciences Ord (RNA) | 6.4 | $96M | 2.1M | 45.93 |
|
|
| Relay Therapeutics (RLAY) | 4.4 | $66M | +9% | 9.3M | 7.08 |
|
| Alnylam Pharmaceuticals (ALNY) | 3.1 | $47M | 170k | 275.03 |
|
|
| EXACT Sciences Corporation (EXAS) | 3.0 | $44M | 650k | 68.12 |
|
|
| Intellia Therapeutics (NTLA) | 2.7 | $41M | 2.0M | 20.55 |
|
|
| Structure Therapeutics Sponsored Ads (GPCR) | 2.0 | $31M | 700k | 43.89 |
|
|
| Blueprint Medicines (BPMC) | 2.0 | $30M | 326k | 92.50 |
|
|
| Denali Therapeutics (DNLI) | 1.9 | $29M | -23% | 990k | 29.13 |
|
| Codexis (CDXS) | 1.7 | $25M | +305% | 8.1M | 3.08 |
|
| Veracyte (VCYT) | 1.5 | $23M | -22% | 666k | 34.04 |
|
| Neurogene (NGNE) | 1.5 | $22M | 525k | 41.96 |
|
|
| Verve Therapeutics (VERV) | 1.3 | $19M | +30% | 4.0M | 4.84 |
|
| Beam Therapeutics (BEAM) | 1.3 | $19M | +14% | 775k | 24.50 |
|
| Tenaya Therapeutics (TNYA) | 0.9 | $13M | 6.7M | 1.93 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 0.8 | $12M | +43% | 1.2M | 10.81 |
|
| 2seventy Bio Common Stock (TSVT) | 0.6 | $9.4M | 2.0M | 4.72 |
|
|
| Tango Therapeutics (TNGX) | 0.6 | $9.2M | 1.2M | 7.70 |
|
|
| Syndax Pharmaceuticals (SNDX) | 0.6 | $9.1M | +216% | 475k | 19.25 |
|
| Guardant Health (GH) | 0.5 | $8.0M | +250% | 350k | 22.94 |
|
| Contineum Therapeutics Cl A (CTNM) | 0.4 | $5.7M | 297k | 19.14 |
|
|
| Century Therapeutics (IPSC) | 0.4 | $5.5M | -38% | 3.2M | 1.71 |
|
| Grail (GRAL) | 0.3 | $4.8M | +337% | 350k | 13.76 |
|
| Absci Corp (ABSI) | 0.2 | $3.7M | 973k | 3.82 |
|
|
| Pacific Biosciences of California (PACB) | 0.1 | $1.8M | 1.0M | 1.70 |
|
|
| Prime Medicine (PRME) | 0.1 | $1.4M | 367k | 3.87 |
|
|
| Exscientia Ads (EXAI) | 0.1 | $1.0M | 214k | 4.88 |
|
|
| Monte Rosa Therapeutics (GLUE) | 0.0 | $456k | -67% | 86k | 5.30 |
|
| Ginkgo Bioworks Holdings Cl A New | 0.0 | $297k | NEW | 37k | 8.15 |
|
| Kronos Bio (KRON) | 0.0 | $124k | 124k | 1.00 |
|
Past Filings by Casdin Capital
SEC 13F filings are viewable for Casdin Capital going back to 2015
- Casdin Capital 2024 Q3 filed Nov. 14, 2024
- Casdin Capital 2024 Q2 restated filed Oct. 18, 2024
- Casdin Capital 2024 Q2 filed Aug. 14, 2024
- Casdin Capital 2024 Q1 filed May 15, 2024
- Casdin Capital 2023 Q4 filed Feb. 14, 2024
- Casdin Capital 2023 Q3 filed Nov. 14, 2023
- Casdin Capital 2023 Q2 filed Aug. 14, 2023
- Casdin Capital 2023 Q1 filed May 15, 2023
- Casdin Capital 2022 Q4 filed Feb. 14, 2023
- Casdin Capital 2022 Q3 filed Nov. 14, 2022
- Casdin Capital 2022 Q2 filed Aug. 15, 2022
- Casdin Capital 2022 Q1 filed May 16, 2022
- Casdin Capital 2021 Q4 filed Feb. 14, 2022
- Casdin Capital 2021 Q3 filed Nov. 15, 2021
- Casdin Capital 2021 Q2 filed Aug. 16, 2021
- Casdin Capital 2021 Q1 filed May 17, 2021